Two Stocks Wall Street Loves and One to Sell
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 57 minutes ago
0mins
Source: Yahoo Finance
- Sell Recommendation for LKQ: LKQ's consensus price target is $40.81, implying a 55.8% return; however, its organic sales performance suggests a need for strategic adjustments or M&A to catalyze growth, while declining returns on capital indicate that recent investments are destroying value.
- Positive Outlook for DexCom: DexCom's consensus price target is $84.67, with a 22.5% implied return, as its organic revenue growth averaged 12.5% over the past two years, and its free cash flow margin has increased by 26 percentage points, showcasing strong market opportunities.
- Strong Fundamentals for Pfizer: Pfizer's consensus price target is $29.19, indicating a 22.2% implied return, supported by a massive revenue base of $63.32 billion in a highly regulated sector, enhancing its negotiating power, while adjusted operating profits have increased over the past two years.
- Market Outlook Analysis: While LKQ faces challenges, the strong fundamentals of DexCom and Pfizer support Wall Street's optimistic outlook, prompting investors to consider the long-term growth potential of these companies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LKQ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LKQ
Wall Street analysts forecast LKQ stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 26.330
Low
33.00
Averages
41.25
High
50.00
Current: 26.330
Low
33.00
Averages
41.25
High
50.00
About LKQ
LKQ Corporation is a provider of alternative and specialty parts to repair and accessorize automobiles and other vehicles. The Company offers its customers a range of original equipment manufacturer (OEM) recycled and aftermarket parts, replacement systems, components, equipment, and services. Its Wholesale - North America segment provides alternative vehicle collision replacement products, paint and body repair related products, and alternative vehicle mechanical replacement products, with its sales, processing, and distribution facilities reaching major markets in the United States and Canada. Its Europe segment provides alternative vehicle replacement and maintenance products in Germany, the United Kingdom, the Benelux region (Belgium, Netherlands, and Luxembourg), Italy, Czech Republic, Austria, Slovakia, France and other European countries. Its Specialty segment is a distributor of specialty vehicle aftermarket equipment and accessories across the United States and Canada.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Two Stocks Wall Street Loves and One to Sell
- Sell Recommendation for LKQ: LKQ's consensus price target is $40.81, implying a 55.8% return; however, its organic sales performance suggests a need for strategic adjustments or M&A to catalyze growth, while declining returns on capital indicate that recent investments are destroying value.
- Positive Outlook for DexCom: DexCom's consensus price target is $84.67, with a 22.5% implied return, as its organic revenue growth averaged 12.5% over the past two years, and its free cash flow margin has increased by 26 percentage points, showcasing strong market opportunities.
- Strong Fundamentals for Pfizer: Pfizer's consensus price target is $29.19, indicating a 22.2% implied return, supported by a massive revenue base of $63.32 billion in a highly regulated sector, enhancing its negotiating power, while adjusted operating profits have increased over the past two years.
- Market Outlook Analysis: While LKQ faces challenges, the strong fundamentals of DexCom and Pfizer support Wall Street's optimistic outlook, prompting investors to consider the long-term growth potential of these companies.
See More
LKQ Corporation Faces Class Action Lawsuit
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against LKQ Corporation and certain officers, alleging violations of federal securities laws on behalf of all investors who purchased LKQ securities between February 27, 2023, and July 23, 2025.
- Allegation Details: The complaint claims that LKQ misrepresented the integration risks associated with its FinishMaster acquisition, asserting that it was a compelling strategic fit that would enhance profitability, which ultimately misled investors about the acquisition's true impact on the company's growth.
- Investor Actions: Affected investors are encouraged to apply to be lead plaintiffs by June 22, 2026, allowing them to share in any potential recovery without needing to serve as lead plaintiffs.
- Law Firm Advantages: Bronstein, Gewirtz & Grossman operates on a contingency fee basis, providing risk-free legal representation for investors, and has successfully recovered hundreds of millions for clients nationwide, showcasing its expertise in securities fraud class actions.
See More
Multiple Companies Face Class Action Lawsuits
- LKQ Corporation Lawsuit: LKQ Corporation is facing a class action lawsuit for failing to disclose significant risks regarding customer losses and declining market share during the period from February 27, 2023, to July 23, 2025, with a lead plaintiff deadline of June 22, 2026, potentially impacting the company's reputation and stock price.
- Regencell Bioscience Lawsuit: Regencell Bioscience Holdings Limited is accused of failing to disclose market manipulation risks from October 28, 2024, to October 31, 2025, exposing investors to significant financial risks, with a lead plaintiff deadline of June 23, 2026, which may trigger regulatory scrutiny.
- Globant S.A. Lawsuit: Globant S.A. is under scrutiny for not disclosing decreasing demand and project cancellations in Latin America from February 15, 2024, to August 14, 2025, leading to investor losses, with a lead plaintiff deadline of June 23, 2026, which could negatively affect future performance.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors that they can contact the firm to discuss their legal rights if they suffered losses during the specified periods, which may influence their legal options and subsequent actions.
See More
Commvault Systems Under Shareholder Investigation for Alleged Misconduct
- Shareholder Investigation Initiated: Grabar Law Office is investigating Commvault Systems, Inc. (NASDAQ: CVLT) for potential breaches of fiduciary duties by its executives, allowing shareholders who purchased shares before April 29, 2025, to seek corporate reforms and fund recovery.
- Allegations of False Statements: A recently filed securities fraud class action alleges that Commvault misled investors through its executives' materially false and misleading statements regarding the true state of its projected ARR growth for fiscal year 2026, leading to investor misconceptions about the company's prospects.
- Negative Market Reaction: The failure to accurately reflect crucial variables in the ARR growth environment has resulted in a significant overstatement of Commvault's financial strength and growth prospects, with investors experiencing multiple financial guidance downgrades between 2024 and 2025.
- Potential Legal Consequences: Should the investigation confirm executive misconduct, the company may face legal liabilities and financial losses, adversely affecting its market reputation and future financing capabilities.
See More
LKQ Corporation Faces Class Action Lawsuit
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against LKQ Corporation and certain officers, alleging violations of federal securities laws from February 27, 2023, to July 23, 2025, seeking damages for affected investors.
- False Statement Allegations: The complaint claims that LKQ misrepresented the integration risks associated with the FinishMaster acquisition, asserting that it was a compelling strategic fit that would enhance profitability, which misled investors about the company's true operational status.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by June 22, 2026, to potentially share in any recovery, with the law firm operating on a contingency fee basis, meaning they only get paid if successful.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman LLC is nationally recognized for representing investors in securities fraud class actions, having recovered hundreds of millions for investors, underscoring their commitment to restoring investor capital and ensuring corporate accountability.
See More
Notice of Class Action Lawsuit for LKQ Corporation Shareholders
- Class Action Notice: The Gross Law Firm has issued a notice encouraging shareholders who purchased LKQ stock between February 27, 2023, and July 23, 2025, to contact them for potential lead plaintiff appointment, highlighting the firm's commitment to shareholder rights.
- Allegations of False Statements: The filed complaint alleges that LKQ made materially false and misleading statements during the class period, which artificially inflated the stock price, indicating serious lapses in corporate governance and transparency.
- Shareholder Losses: Following the disclosure of these misrepresentations, LKQ's stock price declined significantly, causing economic losses to shareholders who bought during the class period, reflecting a loss of market trust in the company.
- Participation Steps: Shareholders must register by June 22, 2026, to participate in the lawsuit, and upon registration, they will receive updates on the case's progress, demonstrating the firm's dedication to protecting investor interests.
See More
Two Stocks Wall Street Loves and One to Sell
- Sell Recommendation for LKQ: LKQ's consensus price target is $40.81, implying a 55.8% return; however, its organic sales performance suggests a need for strategic adjustments or M&A to catalyze growth, while declining returns on capital indicate that recent investments are destroying value.
- Positive Outlook for DexCom: DexCom's consensus price target is $84.67, with a 22.5% implied return, as its organic revenue growth averaged 12.5% over the past two years, and its free cash flow margin has increased by 26 percentage points, showcasing strong market opportunities.
- Strong Fundamentals for Pfizer: Pfizer's consensus price target is $29.19, indicating a 22.2% implied return, supported by a massive revenue base of $63.32 billion in a highly regulated sector, enhancing its negotiating power, while adjusted operating profits have increased over the past two years.
- Market Outlook Analysis: While LKQ faces challenges, the strong fundamentals of DexCom and Pfizer support Wall Street's optimistic outlook, prompting investors to consider the long-term growth potential of these companies.
See More
LKQ Corporation Faces Class Action Lawsuit
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against LKQ Corporation and certain officers, alleging violations of federal securities laws on behalf of all investors who purchased LKQ securities between February 27, 2023, and July 23, 2025.
- Allegation Details: The complaint claims that LKQ misrepresented the integration risks associated with its FinishMaster acquisition, asserting that it was a compelling strategic fit that would enhance profitability, which ultimately misled investors about the acquisition's true impact on the company's growth.
- Investor Actions: Affected investors are encouraged to apply to be lead plaintiffs by June 22, 2026, allowing them to share in any potential recovery without needing to serve as lead plaintiffs.
- Law Firm Advantages: Bronstein, Gewirtz & Grossman operates on a contingency fee basis, providing risk-free legal representation for investors, and has successfully recovered hundreds of millions for clients nationwide, showcasing its expertise in securities fraud class actions.
See More
Multiple Companies Face Class Action Lawsuits
- LKQ Corporation Lawsuit: LKQ Corporation is facing a class action lawsuit for failing to disclose significant risks regarding customer losses and declining market share during the period from February 27, 2023, to July 23, 2025, with a lead plaintiff deadline of June 22, 2026, potentially impacting the company's reputation and stock price.
- Regencell Bioscience Lawsuit: Regencell Bioscience Holdings Limited is accused of failing to disclose market manipulation risks from October 28, 2024, to October 31, 2025, exposing investors to significant financial risks, with a lead plaintiff deadline of June 23, 2026, which may trigger regulatory scrutiny.
- Globant S.A. Lawsuit: Globant S.A. is under scrutiny for not disclosing decreasing demand and project cancellations in Latin America from February 15, 2024, to August 14, 2025, leading to investor losses, with a lead plaintiff deadline of June 23, 2026, which could negatively affect future performance.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors that they can contact the firm to discuss their legal rights if they suffered losses during the specified periods, which may influence their legal options and subsequent actions.
See More
Commvault Systems Under Shareholder Investigation for Alleged Misconduct
- Shareholder Investigation Initiated: Grabar Law Office is investigating Commvault Systems, Inc. (NASDAQ: CVLT) for potential breaches of fiduciary duties by its executives, allowing shareholders who purchased shares before April 29, 2025, to seek corporate reforms and fund recovery.
- Allegations of False Statements: A recently filed securities fraud class action alleges that Commvault misled investors through its executives' materially false and misleading statements regarding the true state of its projected ARR growth for fiscal year 2026, leading to investor misconceptions about the company's prospects.
- Negative Market Reaction: The failure to accurately reflect crucial variables in the ARR growth environment has resulted in a significant overstatement of Commvault's financial strength and growth prospects, with investors experiencing multiple financial guidance downgrades between 2024 and 2025.
- Potential Legal Consequences: Should the investigation confirm executive misconduct, the company may face legal liabilities and financial losses, adversely affecting its market reputation and future financing capabilities.
See More
LKQ Corporation Faces Class Action Lawsuit
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against LKQ Corporation and certain officers, alleging violations of federal securities laws from February 27, 2023, to July 23, 2025, seeking damages for affected investors.
- False Statement Allegations: The complaint claims that LKQ misrepresented the integration risks associated with the FinishMaster acquisition, asserting that it was a compelling strategic fit that would enhance profitability, which misled investors about the company's true operational status.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by June 22, 2026, to potentially share in any recovery, with the law firm operating on a contingency fee basis, meaning they only get paid if successful.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman LLC is nationally recognized for representing investors in securities fraud class actions, having recovered hundreds of millions for investors, underscoring their commitment to restoring investor capital and ensuring corporate accountability.
See More
Notice of Class Action Lawsuit for LKQ Corporation Shareholders
- Class Action Notice: The Gross Law Firm has issued a notice encouraging shareholders who purchased LKQ stock between February 27, 2023, and July 23, 2025, to contact them for potential lead plaintiff appointment, highlighting the firm's commitment to shareholder rights.
- Allegations of False Statements: The filed complaint alleges that LKQ made materially false and misleading statements during the class period, which artificially inflated the stock price, indicating serious lapses in corporate governance and transparency.
- Shareholder Losses: Following the disclosure of these misrepresentations, LKQ's stock price declined significantly, causing economic losses to shareholders who bought during the class period, reflecting a loss of market trust in the company.
- Participation Steps: Shareholders must register by June 22, 2026, to participate in the lawsuit, and upon registration, they will receive updates on the case's progress, demonstrating the firm's dedication to protecting investor interests.
See More
